Previous 10 | Next 10 |
You could play it safe. Put your money in assets that aren't likely to lose their value. Maybe you might opt to buy shares of utility companies that enjoy monopolies. But not every investor wants to take the safe path that leads to smaller returns over the long run. Even normally risk-ave...
Neither Novavax (NASDAQ: NVAX) nor Vaxart (NASDAQ: VXRT) is at the head of the pack of drugmakers developing COVID-19 vaccine candidates. However, both stocks are way ahead of most of their rivals. Novavax shares are up close to 2,700% year to date; Vaxart stock has skyrocketed over 4,...
Reuters reports that the European Union (EU) is negotiating with Moderna (NASDAQ: MRNA ) , Sanofi (NASDAQ: SNY ) , Johnson & Johnson (NYSE: JNJ ) , BioNTech (NASDAQ: BNTX ) and CureVac for advance purchases of their respective COVID-19 vaccines. The EU shared the information yeste...
Shares of Vaxart (NASDAQ: VXRT) are up by 13.2% as of 11:14 a.m. EDT on Thursday, after the company announced the publication of a new study that estimates the annual cost of norovirus gastroenteritis in the U.S. The data from the study in question, published in the Journal of Infectious Di...
SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, and has a Phase 2 ready norovirus vaccine program, today announc...
Gainers: China Finance Online (NASDAQ: JRJC ) +176% . More news on: China Finance Online Co. Limited, Genetic Technologies Limited, WISeKey International Holding AG, Stocks on the move, , Read more ...
Moderna (NASDAQ: MRNA) and Vaxart (NASDAQ: VXRT) are two of the many companies that are pursuing a COVID-19 vaccine. The stock market has already produced a lot of riches for biotech investors in this sector; Moderna's stock has almost quadrupled in six months, while the s...
FinancialBuzz.com News Commentary New York, NY (7/15/2020) – The current pandemic has created the need for new technologies in order to improve population-level screening and patient monitoring. One sector that has emerged in recent years and spiked in popularity this year is telemedici...
Shares of Vaxart (NASDAQ: VXRT) rocketed 40% higher on Tuesday, furthering the biotech company's sharp ascent in recent days. On Monday, Vaxart's stock skyrocketed 52%, following bullish comments by B. Riley FBR analyst Mayank Mamtani. Mamtani began coverage of Vaxart and placed a buy rat...
IMV (NASDAQ: IMV ) +162% rallies on COVID-19 vaccine progress. More news on: IMV Inc., VolitionRx Limited, INmune Bio, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...